Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Therapeutics Company Announces Dissemination of Positive Results From Rhinitis Trial

Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal.
Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company focused on developing and commercializing RNA delivery technology for targets beyond the liver, recently announced the dissemination of positive results from its NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR). These results were shared via video formats on the social media channels of Allergy, one of the highest-ranking journals in the field of allergology worldwide. This announcement follows the journal's April publication of the peer-reviewed article titled "AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial," which detailed the pivotal trial's findings. $Altamira Therapeutics(CYTO.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
1989 Views
Comment
Sign in to post a comment
    150Followers
    0Following
    340Visitors
    Follow